Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Atogepant for Episodic Migraine Prevention
NCT03700320Phase 3Completed
- Sponsor
- Allergan
- Start
- Oct 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atogepant in episodic migraine, sponsored by Allergan. Started Oct 2018; status: completed.
02
Drugs
atogepant
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT03700320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03700320.